Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine
Identifieur interne : 000F56 ( Main/Exploration ); précédent : 000F55; suivant : 000F57Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine
Auteurs : Yasuko Tsunetsugu-Yokota [Japon] ; Kazuo Ohnishi [Japon] ; Toshitada Takemori [Japon]Source :
- Reviews in Medical Virology [ 1052-9276 ] ; 2006-03.
English descriptors
- Teeft :
- Adjuvant, Animal models, Antibody, Antibody response, Assay, Attenuated, Attenuated virus, Basic research, Biochem biophys, Cell repertoire, Clin, Clin diagn, Clin microbiol, Clone, Convalescent, Copyright, Coronavirus, Coronaviruses, Effective vaccine, Elisa, Enzyme immunoassay, Epitope, Epitope mapping, Glycoprotein, Healthy donors, High level, Human coronavirus, Human coronaviruses, Human mabs, Immune, Immune response, Immune responses, Immunised, Immunised mice, Immunising antigen, Immunization, Immunol, Infectious diseases, John wiley sons, Linear epitopes, Mabs, Microbiol, Monoclonal, Monoclonal antibodies, Mouse, Mouse mabs, Mouse model, Murine, Neutralisation, Neutralisation ability, Neutralising, Neutralising activity, Neutralising antibodies, Neutralising antibody, Neutralization, Neutralizing, Neutralizing antibodies, Neutralizing antibody, Nucleocapsid, Nucleocapsid protein, Other hand, Passive transfer, Peptide, Polyclonal, Potent neutralization, Proc natl acad, Protective immunity, Protein, Receptor, Recognises, Recombinant, Respiratory syndrome, Respiratory syndrome coronavirus, Respiratory syndrome coronavirus spike protein, Sars, Sars coronavirus, Sars patients, Scfv, Scfv clones, Spike, Spike glycoprotein, Spike protein, Structural proteins, Syndrome, Vaccine, Vaccinia, Viral, Viral entry, Virion, Virol, Virology, Vivo protection, Wang, Western blot, Whole virion, Whole virions.
Abstract
SARS‐CoV is a new type of human coronavirus identified as a causative agent of severe acute respiratory syndrome (SARS). On the occasion of the SARS outbreak, various monoclonal antibodies (mAbs) against SARS‐CoV have been developed and applied for diagnosis, clinical management and basic research. In this review, we overview the biochemical and functional properties and applications of these SARS‐CoV mAbs. We also focus on a variety of vaccines currently under development and discuss the immune response elicited by these vaccines in animal models, hopefully to better understand what we need to do next to fight against newly emerging pathogens in the future. Copyright © 2006 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/rmv.492
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000427
- to stream Istex, to step Curation: 000407
- to stream Istex, to step Checkpoint: 000223
- to stream Main, to step Merge: 000F62
- to stream Main, to step Curation: 000F56
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine</title><author><name sortKey="Tsunetsugu Okota, Yasuko" sort="Tsunetsugu Okota, Yasuko" uniqKey="Tsunetsugu Okota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name></author><author><name sortKey="Ohnishi, Kazuo" sort="Ohnishi, Kazuo" uniqKey="Ohnishi K" first="Kazuo" last="Ohnishi">Kazuo Ohnishi</name></author><author><name sortKey="Takemori, Toshitada" sort="Takemori, Toshitada" uniqKey="Takemori T" first="Toshitada" last="Takemori">Toshitada Takemori</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CE479B03F68E56BCC212581306B403979670B62F</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/rmv.492</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-5FZF6WNL-0/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000427</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000427</idno><idno type="wicri:Area/Istex/Curation">000407</idno><idno type="wicri:Area/Istex/Checkpoint">000223</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000223</idno><idno type="wicri:doubleKey">1052-9276:2006:Tsunetsugu Okota Y:severe:acute:respiratory</idno><idno type="wicri:Area/Main/Merge">000F62</idno><idno type="wicri:Area/Main/Curation">000F56</idno><idno type="wicri:Area/Main/Exploration">000F56</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine</title><author><name sortKey="Tsunetsugu Okota, Yasuko" sort="Tsunetsugu Okota, Yasuko" uniqKey="Tsunetsugu Okota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Immunology, National Institute of Infectious Diseases, Toyama‐cho, Shinjuku‐ku, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Ohnishi, Kazuo" sort="Ohnishi, Kazuo" uniqKey="Ohnishi K" first="Kazuo" last="Ohnishi">Kazuo Ohnishi</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Immunology, National Institute of Infectious Diseases, Toyama‐cho, Shinjuku‐ku, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Takemori, Toshitada" sort="Takemori, Toshitada" uniqKey="Takemori T" first="Toshitada" last="Takemori">Toshitada Takemori</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Immunology, National Institute of Infectious Diseases, Toyama‐cho, Shinjuku‐ku, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Japon</country></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Correspondence address: Department of Immunology, National Institute of Infectious Diseases, 1‐23‐1 Toyama‐cho, Shinjuku‐ku, Tokyo 162‐8640</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Reviews in Medical Virology</title><title level="j" type="alt">REVIEWS IN MEDICAL VIROLOGY</title><idno type="ISSN">1052-9276</idno><idno type="eISSN">1099-1654</idno><imprint><biblScope unit="vol">16</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="117">117</biblScope><biblScope unit="page" to="131">131</biblScope><biblScope unit="page-count">15</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2006-03">2006-03</date></imprint><idno type="ISSN">1052-9276</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1052-9276</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adjuvant</term><term>Animal models</term><term>Antibody</term><term>Antibody response</term><term>Assay</term><term>Attenuated</term><term>Attenuated virus</term><term>Basic research</term><term>Biochem biophys</term><term>Cell repertoire</term><term>Clin</term><term>Clin diagn</term><term>Clin microbiol</term><term>Clone</term><term>Convalescent</term><term>Copyright</term><term>Coronavirus</term><term>Coronaviruses</term><term>Effective vaccine</term><term>Elisa</term><term>Enzyme immunoassay</term><term>Epitope</term><term>Epitope mapping</term><term>Glycoprotein</term><term>Healthy donors</term><term>High level</term><term>Human coronavirus</term><term>Human coronaviruses</term><term>Human mabs</term><term>Immune</term><term>Immune response</term><term>Immune responses</term><term>Immunised</term><term>Immunised mice</term><term>Immunising antigen</term><term>Immunization</term><term>Immunol</term><term>Infectious diseases</term><term>John wiley sons</term><term>Linear epitopes</term><term>Mabs</term><term>Microbiol</term><term>Monoclonal</term><term>Monoclonal antibodies</term><term>Mouse</term><term>Mouse mabs</term><term>Mouse model</term><term>Murine</term><term>Neutralisation</term><term>Neutralisation ability</term><term>Neutralising</term><term>Neutralising activity</term><term>Neutralising antibodies</term><term>Neutralising antibody</term><term>Neutralization</term><term>Neutralizing</term><term>Neutralizing antibodies</term><term>Neutralizing antibody</term><term>Nucleocapsid</term><term>Nucleocapsid protein</term><term>Other hand</term><term>Passive transfer</term><term>Peptide</term><term>Polyclonal</term><term>Potent neutralization</term><term>Proc natl acad</term><term>Protective immunity</term><term>Protein</term><term>Receptor</term><term>Recognises</term><term>Recombinant</term><term>Respiratory syndrome</term><term>Respiratory syndrome coronavirus</term><term>Respiratory syndrome coronavirus spike protein</term><term>Sars</term><term>Sars coronavirus</term><term>Sars patients</term><term>Scfv</term><term>Scfv clones</term><term>Spike</term><term>Spike glycoprotein</term><term>Spike protein</term><term>Structural proteins</term><term>Syndrome</term><term>Vaccine</term><term>Vaccinia</term><term>Viral</term><term>Viral entry</term><term>Virion</term><term>Virol</term><term>Virology</term><term>Vivo protection</term><term>Wang</term><term>Western blot</term><term>Whole virion</term><term>Whole virions</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">SARS‐CoV is a new type of human coronavirus identified as a causative agent of severe acute respiratory syndrome (SARS). On the occasion of the SARS outbreak, various monoclonal antibodies (mAbs) against SARS‐CoV have been developed and applied for diagnosis, clinical management and basic research. In this review, we overview the biochemical and functional properties and applications of these SARS‐CoV mAbs. We also focus on a variety of vaccines currently under development and discuss the immune response elicited by these vaccines in animal models, hopefully to better understand what we need to do next to fight against newly emerging pathogens in the future. Copyright © 2006 John Wiley & Sons, Ltd.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement></list><tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Tsunetsugu Okota, Yasuko" sort="Tsunetsugu Okota, Yasuko" uniqKey="Tsunetsugu Okota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name></region><name sortKey="Ohnishi, Kazuo" sort="Ohnishi, Kazuo" uniqKey="Ohnishi K" first="Kazuo" last="Ohnishi">Kazuo Ohnishi</name><name sortKey="Takemori, Toshitada" sort="Takemori, Toshitada" uniqKey="Takemori T" first="Toshitada" last="Takemori">Toshitada Takemori</name><name sortKey="Takemori, Toshitada" sort="Takemori, Toshitada" uniqKey="Takemori T" first="Toshitada" last="Takemori">Toshitada Takemori</name><name sortKey="Takemori, Toshitada" sort="Takemori, Toshitada" uniqKey="Takemori T" first="Toshitada" last="Takemori">Toshitada Takemori</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F56 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F56 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CE479B03F68E56BCC212581306B403979670B62F
|texte= Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine
}}
| This area was generated with Dilib version V0.6.33. |  |